MedTrace Logo

AAA Rupture Risk Assessment in COVID-19 Pandemic

NCT05197543 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2022-01-25

No results posted yet for this study

Summary

The acute phase of the COVID-19 pandemic requires a redefinition of healthcare system to increase the number of available intensive care units for COVID-19 patients. This leads to the postponing of elective surgeries including the treatment of abdominal aortic aneurysm (AAA). The probabilistic rupture risk index (PRRI) recently showed its advantage over the diameter criterion in AAA rupture risk assessment. Its major improvement is in increased specificity and yet has the same sensitivity as the maximal diameter criterion. The objective of this study was to test the clinical applicability of the PRRI diagnostic method in a quasi-prospective observational patient cohort study.

Conditions

Interventions

DIAGNOSTIC_TEST

Biomechanical rupture risk assessment

3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.

Sponsors & Collaborators

  • VSB - Technical University of Ostrava

    collaborator UNKNOWN

  • Masaryk University

    lead OTHER

Principal Investigators

  • Robert Staffa, M.D., Ph.D. · Masaryk University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2021-12-17
Completion
2022-03-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05197543 on ClinicalTrials.gov